REGN SEC Filing News — Regeneron Pharmaceuticals, Inc.

Latest SEC filings for Regeneron Pharmaceuticals, Inc. (REGN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-06.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul…
Sector: Healthcare Industry: Biotechnology Market Cap: $77.0B CIK: 872589
20
Total Filings
0
Bullish Classifications
6
Bearish Classifications
8
Insider Transactions
5
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for REGN currently lean bearish. Of the 20 filing records displayed, 6 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
REGN Filing Activity Snapshot 2026-05-04 — 2026-10-06
Insider Transactions (Form 4)
0 buys vs 6 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$2.00M
McCourt Marion (EVP Commercial) · 2026-09-03
2,346 shares · Form 4
Form 144 Notices
6
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Regeneron Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 6 open-market sale and 2 option exercise. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×6
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×2
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Open-market sale Insider Selling 2026-09-03

REGN insider McCourt Marion (EVP Commercial) sold 2,346 shares (~$2.00M)

McCourt Marion, listed as EVP Commercial at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 2,346 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,215 $850.00 $1.03M
S Open-market sale 1,131 $857.39 $969.7K
Filing: Form 4 (Insider Transaction) Insider: McCourt Marion (EVP Commercial) Shares: 2,346 Est. Value: $2.00M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-03

REGN insider Guarini Kathryn (Director) sold 400 shares (~$340.0K)

Guarini Kathryn, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 400 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 400 $719.37 $287.7K
S Open-market sale 400 $850.00 $340.0K
M Option exercise derivative · Non-Qualified Stock Option (right to buy) 400 — —
Filing: Form 4 (Insider Transaction) Insider: Guarini Kathryn (Director) Shares: 400 Est. Value: $340.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-21

REGN insider Form 4 filed for equity award, exercise, or tax withholding

LAROSA JOSEPH J (EVP General Counsel and Secret) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 12,282 $381.92 $4.69M
F Tax withholding on vested shares 9,019 $830.15 $7.49M
M Option exercise derivative · Non-Qualified Stock Option (right to buy) 12,282 — —
Filing: Form 4 (Insider Transaction) Insider: LAROSA JOSEPH J (EVP General Counsel and Secret) Shares: 21,301
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-20

REGN insider Form 4 filed for equity award, exercise, or tax withholding

Fenimore Christopher R. (EVP Finance CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 6,283 $381.92 $2.40M
F Tax withholding on vested shares 4,599 $813.47 $3.74M
M Option exercise derivative · Non-Qualified Stock Option (right to buy) 6,283 — —
Filing: Form 4 (Insider Transaction) Insider: Fenimore Christopher R. (EVP Finance CFO) Shares: 10,882
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

REGN insider Guarini Kathryn (Director) sold 400 shares (~$320.0K)

Guarini Kathryn, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 400 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 400 $719.37 $287.7K
S Open-market sale 400 $800.00 $320.0K
M Option exercise derivative · Non-Qualified Stock Option (right to buy) 400 — —
Filing: Form 4 (Insider Transaction) Insider: Guarini Kathryn (Director) Shares: 400 Est. Value: $320.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

REGN insider Zoghbi Huda Y (Director) sold 800 shares (~$640.0K)

Zoghbi Huda Y, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 800 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 800 $376.69 $301.4K
S Open-market sale 800 $800.00 $640.0K
M Option exercise derivative · Non-Qualified Stock Option (right to buy) 800 — —
Filing: Form 4 (Insider Transaction) Insider: Zoghbi Huda Y (Director) Shares: 800 Est. Value: $640.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-07

REGN insider RYAN ARTHUR F (Director) sold 200 shares (~$130.0K)

RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 200 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 200 $650.15 $130.0K
Filing: Form 4 (Insider Transaction) Insider: RYAN ARTHUR F (Director) Shares: 200 Est. Value: $130.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-04

REGN insider RYAN ARTHUR F (Director) sold 100 shares (~$70.5K)

RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5 $701.76 $3.5K
S Open-market sale 15 $702.46 $10.5K
S Open-market sale 24 $703.46 $16.9K
S Open-market sale 15 $704.28 $10.6K
S Open-market sale 14 $705.56 $9.9K
S Open-market sale 7 $706.74 $4.9K
S Open-market sale 4 $707.40 $2.8K
S Open-market sale 6 $709.45 $4.3K
S Open-market sale 2 $710.87 $1.4K
S Open-market sale 5 $711.49 $3.6K
S Open-market sale 1 $712.09 $712.09
S Open-market sale 2 $714.13 $1.4K
Filing: Form 4 (Insider Transaction) Insider: RYAN ARTHUR F (Director) Shares: 100 Est. Value: $70.5K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Regeneron Pharmaceuticals, Inc. has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-03

REGN Form 144 filed for proposed insider sale by McCourt Marion (1,131 shares) ~$969.3K

McCourt Marion filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: McCourt Marion Shares: 1,131 Est. Value: $969.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-02

REGN Form 144 filed for proposed insider sale by McCourt Marion (1,215 shares) ~$1.03M

McCourt Marion filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: McCourt Marion Shares: 1,215 Est. Value: $1.03M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-02

REGN Form 144 filed for proposed insider sale by Guarini Kathryn (400 shares) ~$340.0K

Guarini Kathryn filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Guarini Kathryn Shares: 400 Est. Value: $340.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-10

REGN Form 144 filed for proposed insider sale by Zoghbi Huda Y (800 shares) ~$640.0K

Zoghbi Huda Y filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Zoghbi Huda Y Shares: 800 Est. Value: $640.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-10

REGN Form 144 filed for proposed insider sale by Guarini Kathryn (400 shares) ~$320.0K

Guarini Kathryn filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Guarini Kathryn Shares: 400 Est. Value: $320.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-02

REGN Form 144 filed for proposed insider sale by Arthur F. Ryan (400 shares) ~$249.9K

Arthur F. Ryan filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Arthur F. Ryan Shares: 400 Est. Value: $249.9K
View on SEC EDGAR → Open Filing Document →
Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for Regeneron Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-06

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-30

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-30

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-06

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-17

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Regeneron Pharmaceuticals, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-30

REGN filed Quarterly Report (10-Q)

REGENERON PHARMACEUTICALS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Regeneron Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on REGN. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — REGN SEC Filings

What SEC filings does Regeneron Pharmaceuticals, Inc. submit to the SEC?

Regeneron Pharmaceuticals, Inc. (REGN) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about REGN?

A Form 4 for REGN discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Regeneron Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for REGN?

The 10-K is Regeneron Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all REGN SEC filings directly on EDGAR?

You can view all historical Regeneron Pharmaceuticals, Inc. filings on the SEC EDGAR company page for REGN. Each filing card on this page links directly to the original SEC document.

How often does Regeneron Pharmaceuticals, Inc. file with the SEC?

Regeneron Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling REGN shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for REGN

REGN Full Stock Analysis REGN Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper REGN analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the REGN stock analysis page.

REGN Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer